Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease
Identifieur interne : 002266 ( Main/Corpus ); précédent : 002265; suivant : 002267Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease
Auteurs : Robert A. Hauser ; Nicholas H. G. HolfordSource :
- Movement Disorders [ 0885-3185 ] ; 2002-09.
English descriptors
- KwdEn :
Abstract
In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society
Url:
DOI: 10.1002/mds.10226
Links to Exploration step
ISTEX:969C0A43C655961DDDB54DBB7E47A23BB3710F9CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Holford, Nicholas H G" sort="Holford, Nicholas H G" uniqKey="Holford N" first="Nicholas H. G." last="Holford">Nicholas H. G. Holford</name><affiliation><mods:affiliation>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:969C0A43C655961DDDB54DBB7E47A23BB3710F9C</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10226</idno><idno type="url">https://api.istex.fr/document/969C0A43C655961DDDB54DBB7E47A23BB3710F9C/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002266</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</mods:affiliation></affiliation></author><author><name sortKey="Holford, Nicholas H G" sort="Holford, Nicholas H G" uniqKey="Holford N" first="Nicholas H. G." last="Holford">Nicholas H. G. Holford</name><affiliation><mods:affiliation>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09">2002-09</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="961">961</biblScope><biblScope unit="page" to="968">968</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">969C0A43C655961DDDB54DBB7E47A23BB3710F9C</idno><idno type="DOI">10.1002/mds.10226</idno><idno type="ArticleID">MDS10226</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>bromocriptine</term><term>disease progress</term><term>levodopa–carbidopa</term><term>long duration response</term><term>neuroprotection</term><term>quantitative model</term><term>selegiline</term><term>washout</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Robert A. Hauser MD</name><affiliations><json:string>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</json:string></affiliations></json:item><json:item><name>Nicholas H.G. Holford MB, ChB</name><affiliations><json:string>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>washout</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>long duration response</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>levodopa–carbidopa</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>bromocriptine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>selegiline</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>quantitative model</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>disease progress</value></json:item></subject><articleId><json:string>MDS10226</json:string></articleId><language><json:string>eng</json:string></language><abstract>In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society</abstract><qualityIndicators><score>6.251</score><pdfVersion>1.4</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>9</keywordCount><abstractCharCount>1341</abstractCharCount><pdfWordCount>3399</pdfWordCount><pdfCharCount>21415</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>196</abstractWordCount></qualityIndicators><title>Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>17</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>968</last><first>961</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Research Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2002</publicationDate><copyrightDate>2002</copyrightDate><doi><json:string>10.1002/mds.10226</json:string></doi><id>969C0A43C655961DDDB54DBB7E47A23BB3710F9C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/969C0A43C655961DDDB54DBB7E47A23BB3710F9C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/969C0A43C655961DDDB54DBB7E47A23BB3710F9C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/969C0A43C655961DDDB54DBB7E47A23BB3710F9C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>2002</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title><author><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</p></note><affiliation>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</affiliation></author><author><persName><forename type="first">Nicholas H.G.</forename><surname>Holford</surname></persName><roleName type="degree">MB, ChB</roleName><affiliation>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-09"></date><biblScope unit="volume">17</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="961">961</biblScope><biblScope unit="page" to="968">968</biblScope></imprint></monogr><idno type="istex">969C0A43C655961DDDB54DBB7E47A23BB3710F9C</idno><idno type="DOI">10.1002/mds.10226</idno><idno type="ArticleID">MDS10226</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2002</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>washout</term></item><item><term>long duration response</term></item><item><term>Parkinson's disease</term></item><item><term>levodopa–carbidopa</term></item><item><term>bromocriptine</term></item><item><term>selegiline</term></item><item><term>neuroprotection</term></item><item><term>quantitative model</term></item><item><term>disease progress</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2001-10-15">Received</change><change when="2002-03-01">Registration</change><change when="2002-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/969C0A43C655961DDDB54DBB7E47A23BB3710F9C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/mds.v17:5</doi><numberingGroup><numbering type="journalVolume" number="17">17</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="2002-09">September/October 2002</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.10226</doi><idGroup><id type="unit" value="MDS10226"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Article</title></titleGroup><copyright ownership="thirdParty">Copyright © 2002 Movement Disorders Society</copyright><eventGroup><event type="manuscriptReceived" date="2001-10-15"></event><event type="manuscriptRevised" date="2002-02-27"></event><event type="manuscriptAccepted" date="2002-03-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2002-04-25"></event><event type="firstOnline" date="2002-04-25"></event><event type="publishedOnlineFinalForm" date="2002-09-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.5 mode:FullText source:FullText result:FullText mathml2tex" date="2010-04-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">961</numbering><numbering type="pageLast">968</numbering></numberingGroup><correspondenceTo>Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS10226.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="14"></count><count type="wordTotal" number="3272"></count></countGroup><titleGroup><title type="main" xml:lang="en">Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title><title type="short" xml:lang="en">Quantitation of Loss of Clinical Benefit</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD</degrees></personName><contactDetails><email>rhauser@hsc.usf.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Nicholas H.G.</givenNames><familyName>Holford</familyName><degrees>MB, ChB</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="NZ" type="organization"><unparsedAffiliation>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">washout</keyword><keyword xml:id="kwd2">long duration response</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">levodopa–carbidopa</keyword><keyword xml:id="kwd5">bromocriptine</keyword><keyword xml:id="kwd6">selegiline</keyword><keyword xml:id="kwd7">neuroprotection</keyword><keyword xml:id="kwd8">quantitative model</keyword><keyword xml:id="kwd9">disease progress</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Quantitation of Loss of Clinical Benefit</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Neurology, Pharmacology, and Experimental Therapeutics, University of South Florida and Tampa General Healthcare, Tampa, Florida, USA</affiliation><description>Correspondence: Parkinson's Disease and Movement Disorders Center, University of South Florida, 4 Columbia Drive, Suite 410, Tampa, FL 33606</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicholas H.G.</namePart><namePart type="family">Holford</namePart><namePart type="termsOfAddress">MB, ChB</namePart><affiliation>Division of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">2002-09</dateIssued><dateCaptured encoding="w3cdtf">2001-10-15</dateCaptured><dateValid encoding="w3cdtf">2002-03-01</dateValid><copyrightDate encoding="w3cdtf">2002</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">2</extent><extent unit="references">14</extent><extent unit="words">3272</extent></physicalDescription><abstract lang="en">In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient duration to ensure elimination of all symptomatic effects. To assess the time course of resolution of symptomatic effects, we evaluated 31 patients with early Parkinson's disease for 2 weeks following discontinuation of levodopa–carbidopa and bromocriptine after 14 months of treatment. Patients had previously been randomly assigned to treatment with selegiline or placebo, and these had been discontinued 2 months earlier. Data from 20 patients with a clear washout of clinical benefit were used to investigate quantitative models describing the time course of total (Activities of Daily Living + motor) Unified Parkinson's Disease Rating Scale score change. The mean half‐life of loss of clinical benefit was 7.9 days (95% confidence interval, 2.2–30.4 days). This indicates that a washout period of 32 days (4 half‐lives) may be required to eliminate approximately 90% of the long‐term symptomatic effects of levodopa–carbidopa and bromocriptine following their withdrawal from patients with early Parkinson's disease. © 2002 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>washout</topic><topic>long duration response</topic><topic>Parkinson's disease</topic><topic>levodopa–carbidopa</topic><topic>bromocriptine</topic><topic>selegiline</topic><topic>neuroprotection</topic><topic>quantitative model</topic><topic>disease progress</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>17</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>961</start><end>968</end><total>8</total></extent></part></relatedItem><identifier type="istex">969C0A43C655961DDDB54DBB7E47A23BB3710F9C</identifier><identifier type="DOI">10.1002/mds.10226</identifier><identifier type="ArticleID">MDS10226</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2002 Movement Disorders Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002266 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002266 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:969C0A43C655961DDDB54DBB7E47A23BB3710F9C
|texte= Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |